M&A / Acquisition · Global (LMICs) · Announced 28 Oct 2026
DKSH → Roche
DKSH buys the rights to Roche's Rocephin (ceftriaxone) antibiotic across 80+ markets including MENA and Africa (~CHF 61m 2025 sales), expanding its higher-margin Healthcare Own Brands portfolio.
Parties: DKSH Holding AG (Switzerland) → Roche (Switzerland)
- Deal type
- M&A / Acquisition
- Value
- Undisclosed
- Territory
- 80+ markets across Asia Pacific, Europe, Africa, the Middle East and Latin America
- Therapeutic area
- Other
- Asset
- Rocephin (ceftriaxone)
- Announced
- 28 Oct 2026
Our analysis
Why this matters
DKSH, the Zurich-based market-expansion group, has acquired the rights to Rocephin (ceftriaxone) — Roche's historic first blockbuster antibiotic — across more than 80 markets spanning Asia Pacific, Europe, Africa, the Middle East and Latin America.
Rocephin generated about $74 m in 2025 net sales.
The full analysis is free to read with a work email on this page.
Source: DKSH media release